MeiraGTx (MGTX) Stock Price, News & Analysis

Company Overview

MeiraGTx Holdings plc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases with limited treatment options. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes to targeted tissues, with an emphasis on disorders affecting the central nervous system, the eye and other organs.

MeiraGTx’s pipeline has included botaretigene sparoparvovec, an investigational AAV-based gene therapy for X-linked retinitis pigmentosa caused by mutations in the RPGR gene. The company has also pursued gene therapy programs for neurological and neurodegenerative conditions, including Parkinson’s disease, as well as additional rare and potentially serious diseases. Its research platform includes technologies designed to regulate gene expression, which may help control the timing and amount of therapeutic proteins produced after treatment.

Founded in 2015, MeiraGTx operates internationally, with activities in the United States and the United Kingdom. The company has established research, development and manufacturing capabilities to support its gene therapy programs and has entered into collaborations with larger pharmaceutical companies, including Johnson & Johnson. Alexandria Forbes is a co-founder and has served as the company’s president and chief executive officer.

Key Stats

• Today's Range: $10.68 to $11.28
• 50-Day Range: $11.05 to $14.97
• 52-Week Range: $6.62 to $15.35
• Volume: 924,578 shs
• Average Volume: 734,952 shs
• Market Capitalization: $1.05 billion
• P/E Ratio: 15.44
• Dividend Yield: N/A
• Price Target: $24.71
• Consensus Rating: Moderate Buy

MeiraGTx Stock Analysis - MarketRank™

MeiraGTx scored higher than 76% of companies evaluated by MarketBeat, and ranked 152nd out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

MeiraGTx has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 5 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

MeiraGTx has a consensus price target of $24.71, representing about 126.3% upside from its current price of $10.92.

Amount of Analyst Coverage

MeiraGTx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MeiraGTx are expected to decrease in the coming year, from $0.30 to ($2.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MeiraGTx is 15.39, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.93.

Price to Earnings Ratio vs. Sector

The P/E ratio of MeiraGTx is 15.39, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.04.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.51% of the float of MeiraGTx has been sold short.

Short Interest Ratio / Days to Cover

MeiraGTx has a short interest ratio ("days to cover") of 6.08.

Change versus previous month

Short interest in MeiraGTx has recently increased by 7.75%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MeiraGTx does not currently pay a dividend.

Dividend Growth

MeiraGTx does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.40

News Sentiment

MeiraGTx has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for MeiraGTx this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for MGTX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

3 people have added MeiraGTx to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, MeiraGTx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,969,233.00 in company stock.

Percentage Held by Insiders

7.40% of the stock of MeiraGTx is held by insiders.

Percentage Held by Institutions

67.48% of the stock of MeiraGTx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/25/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MGTX
• CIK: 1735438
• Web: www.meiragtx.com
• Phone: (646) 860-7985
• Fax: N/A
• Employees: 393
• Year Founded: 2015

Price Target and Rating

• Average Price Target for MeiraGTx: $24.71
• High Price Target: $35.00
• Low Price Target: $16.00
• Potential Upside/Downside: +126.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.71
• Trailing P/E Ratio: 15.44
• Forward P/E Ratio: 36.38
• P/E Growth: N/A
• Net Income: -$114.20 million
• Net Margins: 19.87%
• Pretax Margin: 20.45%
• Return on Equity: 283.85%
• Return on Assets: 29.39%

Debt

• Debt-to-Equity Ratio: 0.46
• Current Ratio: 3.76
• Quick Ratio: 3.76

Sales & Book Value

• Annual Sales: $81.39 million
• Price / Sales: 12.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.07) per share
• Price / Book: -155.90

Miscellaneous

• Outstanding Shares: 96,040,000
• Free Float: 88,936,000
• Market Cap: $1.05 billion
• Optionable: Optionable
• Beta: 1.27